Implantable construct for architectural control of re-vascularization of ischemic

用于缺血性血运重建的结构控制的植入结构

• 批准号: 8522810
• 负责人: Michael Yang
• 金额: $ 18.91万
• 依托单位: INNOLIGN BIOMEDICAL, LLC
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8522810
• 关键词: Absorbable Implants; Achievement; Address; American; Angioplasty; Animal Model; Architecture; Arteries; Biocompatible Materials; Blood; Blood Vessels; Blood flow; Bypass; Cardiac; Cardiac Myocytes; Cause of Death; Characteristics; Computer Architectures; Coronary Artery Bypass; Coronary Circulation; Data; Development; Disease; Endothelial Cells; Engineering; Fatty acid glycerol esters; Feasibility Studies; Future; Goals; Gold; Heart; Heart Diseases; Implant; Ischemia; Life; Morbidity - disease rate; Myocardial; Myocardial Ischemia; Myocardium; Operative Surgical Procedures; Patients; Pattern; Perfusion; Phase; Pilot Projects; Positioning Attribute; Production; Reperfusion Therapy; Research; Schedule; Site; Small Business Technology Transfer Research; Specific qualifier value; Staging; Surgeon; System; Technology; Testing; Time; Tissue Engineering; Tissues; United States; Vascular blood supply; Vascularization; Work; cost; efficacy testing; implantation; mortality; neovascularization; novel; point of care; public health relevance; standard care; subcutaneous; success; trafficking

DESCRIPTION (provided by applicant): Innolign Biomedical has developed an implantable product using novel tissue engineering technologies that spatially direct vascularization and will use the product in the treatment of ischemic conditions. The goal of this Phase I STTR proposal is to establish the feasibility of using this novel templated biomaterial, termed MicroBridge, to treat cardiac ischemia. More than 20 million Americans suffer from the ischemic heart disease with an estimated cost burden surpassing $60 billion annually. Despite substantial progress in angioplasty and bypass surgery to rescue perfusion to the coronary circulation, ischemic heart disease remains the leading cause of mortality and morbidity. MicroBridge will serve as an adjunct delivered during coronary artery bypass surgery that would direct vascularization in the microvasculature to reperfuse regions of ischemia not reached by large artery bypass alone. The product consists of pre- specified architectures of networks of aligned cords of endothelial cells and matrix within a biodegradable implant. Upon implantation, the architectural template of MicroBridge guides new vessels to rapidly grow from a well perfused region to an ischemic region. The goal of Aim 1 is to test the capability of the MicroBridge product to vascularize and reperfuse ischemic tissue in an animal model of cardiac ischemia. The goal of Aim 2 is to establish the stability of the MicroBridge product under specific storage conditions. These studies will set the stage for further development of the MicroBridge product as a treatment for cardiac ischemia.

描述（由申请人提供）：Innolign Biomedical已开发出一种使用新型组织工程技术的植入式产品，该技术可在空间上引导血管形成，并将该产品用于治疗缺血性疾病。该I期STTR提案的目标是确定使用这种新型模板生物材料（称为MicroBridge）治疗心脏缺血的可行性。超过2000万美国人患有缺血性心脏病，估计每年的费用负担超过600亿美元。尽管血管成形术和旁路手术在挽救冠状动脉循环灌注方面取得了实质性进展，但缺血性心脏病仍然是死亡率和发病率的主要原因。MicroBridge将作为冠状动脉旁路手术期间输送的辅助器械，引导微血管系统中的血管化，以再灌注单独大动脉旁路手术无法到达的缺血区域。该产品由可生物降解植入物内的内皮细胞和基质的对齐索网络的预定结构组成。植入后，MicroBridge的结构模板引导新血管从灌注良好的区域快速生长到缺血区域。目标1的目的是在心肌缺血动物模型中测试MicroBridge产品血管化和再灌注缺血组织的能力。目的2旨在确定MicroBridge产品在特定储存条件下的稳定性。这些研究将为MicroBridge产品作为心脏缺血治疗的进一步开发奠定基础。